Jun 4, 2026 · 41 min
Psychiatry shifts focus from chemical imbalances to rewiring neural circuits
Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams
As traditional pharmaceuticals fall short for millions, new circuit-targeted therapies offer rapid and lasting relief for treatment-resistant depression and PTSD.
- 1Psychiatry is transitioning to a circuit-based model that targets specific brain networks directly.
- 2Transcranial Magnetic Stimulation offers a non-invasive way to physically stimulate and rewire underactive neural pathways.
- 3Psychedelics like psilocybin and ibogaine act as powerful catalysts for rapid, therapeutic neuroplasticity.
Don't miss
Dr. Nolan Williams details the shift to Psychiatry 3.0, where neuromodulation and psychedelics physically remodel faulty brain circuits.
The brief
Modern psychiatry is undergoing a paradigm shift from chemical imbalance models to a focus on brain circuitry, ushering in an era of targeted neuromodulation to treat severe mental health conditions.
Dr. Nolan Williams explains that technologies like Transcranial Magnetic Stimulation can physically stimulate and rewire underactive brain networks to rapidly alleviate deep depression.
Alongside hardware-based stimulation, powerful compounds like MDMA, psilocybin, and ibogaine are being studied for their ability to induce rapid neuroplasticity and heal trauma.
By combining precise electrical stimulation with psychedelic-assisted therapy, clinicians aim to achieve durable, long-term remission for treatment-resistant PTSD and depression.
What was said on this episode
35 statements · 26 positive · 5 negative · 2 mixed · 2 neutral
Depression is the world’s most disabling condition.
“Depression is the most disabling condition worldwide.”
Listen at 0:56
The American Heart Association recognizes depression as a major coronary artery disease risk factor.
“the American Heart association added depression as the fourth major risk factor for coronary artery disease.”
Listen at 1:11
Transcranial magnetic stimulation can decelerate heart rate.
“with transcranial magnetic stimulation, a form of brain stimulation, we can actually decelerate the heart rate.”
Listen at 1:40
The heart appears to be the terminal organ of dorsolateral prefrontal cortex signaling.
“the heart very consistently seems to be the end organ of the dorsolateral prefrontal cortex.”
Listen at 3:54
TMS is an especially promising approach for depression-related cognitive regulation.
“TMS is really interesting, actually.”
Listen at 4:24
TMS restores left dorsolateral prefrontal control over the cingulate area.
“What we see with TMS over that region is that we just exogenously do the same sort of thing. We restore the governance of the left dorsolateral over the cingulate area.”
Listen at 5:47
Greater left dorsolateral retiming produces a stronger antidepressant effect.
“the more of an antidepressant effect you have.”
Listen at 6:10
Repeated TMS stimulation functions similarly to brain exercise.
“TMS is almost like exercise for the brain, right?”
Listen at 6:12
SSRIs improve depression and several anxiety-related disorders in some patients.
“SSRIs clearly work, you know, many, many meta analyses kind of proving that out”
Listen at 9:48
SSRIs do not produce therapeutic effects on the day treatment begins.
“they don't work immediately, right? So they don't work like the same day you start taking them.”
Listen at 10:14
Depression is not caused by a congenital serotonin deficit or chemical imbalance.
“There's not a deficit of serotonin. You're not born with what people call a chemical imbalance.”
Listen at 10:31
TMS can work without introducing serotonin into the brain.
“TMS works and there's no serotonin coming in or out of the brain.”
Listen at 12:12
Psilocybin and ketamine are associated with circuit-level brain changes after the drugs leave the body.
“there are a lot of groups that are actually doing neuroimaging before and after, and they're able to see circuit level changes for something like psilocybin or ketamine long after the drug is gone”
Listen at 12:57
People with psychiatric illnesses can recover.
“People can get better.”
Listen at 14:16
TMS and psychedelic treatments can restore normal mood within five days or less.
“people are actually in normal levels of mood for sustained periods of time within five days, within five or less days.”
Listen at 14:22
MDMA and psilocybin appear to produce relatively long-lasting therapeutic effects for trauma-related phenomena.
“some new, like mdma, some that have been around for thousands of years, like psilocybin, seem to have a therapeutic effect that seems to be pretty long lasting for these phenomenon.”
Listen at 16:57
One to several MDMA sessions appear to reduce PTSD symptoms.
“MDMA appears to, in one to a few MDMA sessions, have an anti PTSD effect”
Listen at 18:25
Approximately two-thirds of participants experienced clinically significant PTSD improvement.
“It's about 2/3 of people had a clinically significant change in their ptsd.”
Listen at 19:13
MDMA-related PTSD improvements lasted years for some participants.
“it seemed to last for kind of in the years range for some people.”
Listen at 19:25
A single ketamine infusion produces antidepressant effects lasting about one and a half weeks on average.
“with ketamine, which only on average lasts about a week and a half for a single infusion”
Listen at 19:32
Open-label psilocybin studies report improvement in roughly half to two-thirds of participants.
“it's closer to half to 2/3 of people end up getting better depending upon their level of treatment.”
Listen at 20:09
Blinded psilocybin trials report improvement in approximately one-third of participants.
“In the blinded trials, it was more like a third or so of people.”
Listen at 20:14
Psychedelics produce an overall decrease in brain activity.
“what they found is the opposite, right? There's kind of a, an overall decrease in the level of activity in the brain with psychedelics.”
Listen at 22:01
Psychedelics increase global brain connectivity.
“the connectivity kind of global connectivity kind of increases.”
Listen at 22:32
Psilocybin and TMS appear to share a convergent antidepressant mechanism.
“suggesting there's a convergent mechanism.”
Listen at 23:38
Ibogaine appears exceptionally potent but carries unusually high risk because of cardiac effects.
“ibogaine is kind of both seemingly the most potent and most, seemingly to me at least most powerful psychedelic, but the one that has the most risk too, because it has a cardiac effect.”
Listen at 26:10
Electrocardiogram screening can substantially reduce ibogaine-related cardiac risk.
“you can screen people out that have risk off of their electrocardiogram and reduce the risk quite a bit.”
Listen at 26:27
If validated, psychedelic-assisted cognitive reexamination will likely be considered a psychiatric breakthrough.
“if it is true, then it's very likely that this will be seen as a breakthrough”
Listen at 28:56
Psychedelics such as ibogaine should not be used recreationally.
“these drugs can't be recreational drugs. They really shouldn't be recreational drugs.”
Listen at 29:14
Ayahuasca appears to be safe based on available observations.
“it appears to be safe.”
Listen at 33:11
Ayahuasca exposure was associated with lower prisoner recidivism than control treatment.
“the recidivism rate or the return to prison rate in the ayahuasca exposed individuals was statistically significantly lower than the recidivism rate in the control group”
Listen at 33:54
SAINT can produce remission within one to five days.
“within one to five days”
Listen at 38:42
SAINT produces full mood remission in roughly 60% to 90% of cases.
“somewhere between 60 and 90% of the time they will go into full on remission”
Listen at 38:48
Some SAINT-treated patients have remained in remission for one to four years.
“for some people, we've had four years of remission, a year of remission”
Listen at 39:04
Patients report no side effects and feeling normal after completing SAINT.
“people, when they kind of exit out of that, they end up, they end up saying they don't have any side effects from it and they feel back to normal.”
Listen at 39:55
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.